Overview

Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

This study is a multi-site, randomized, opened and parallel-controlled clinical study. The patients up to the inclusion criteria are randomly treated with Solifenacin Succinate Tablets (5mg/d) or Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks. Before the dosing and at Week 4, 8 and 12 of the dosing, various examinations are made, and various indices are evaluated.

Phase:

Phase 4

Details

Lead Sponsor:

Peking Union Medical College Hospital

Collaborators:

Astellas Pharma China, Inc.
Beijing CAT Science Co., Ltd.

Treatments:

Estrogens
Solifenacin Succinate